ICCM vs. NVRO, SGHT, DRTS, TLSI, BWAY, SKIN, AVR, LAKE, INGN, and PROF
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include Nevro (NVRO), Sight Sciences (SGHT), Alpha Tau Medical (DRTS), TriSalus Life Sciences (TLSI), BrainsWay (BWAY), Beauty Health (SKIN), Anteris Technologies Global (AVR), Lakeland Industries (LAKE), Inogen (INGN), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.
IceCure Medical vs. Its Competitors
Nevro (NYSE:NVRO) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
Nevro has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.
Nevro has a net margin of -16.54% compared to IceCure Medical's net margin of -376.85%. Nevro's return on equity of -23.52% beat IceCure Medical's return on equity.
In the previous week, IceCure Medical had 2 more articles in the media than Nevro. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Nevro. IceCure Medical's average media sentiment score of 1.08 beat Nevro's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.
95.5% of Nevro shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 3.2% of Nevro shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Nevro received 477 more outperform votes than IceCure Medical when rated by MarketBeat users. However, 96.43% of users gave IceCure Medical an outperform vote while only 62.07% of users gave Nevro an outperform vote.
IceCure Medical has lower revenue, but higher earnings than Nevro. IceCure Medical is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
Nevro presently has a consensus target price of $5.36, indicating a potential downside of 8.29%. IceCure Medical has a consensus target price of $2.50, indicating a potential upside of 153.81%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Nevro.
Summary
Nevro and IceCure Medical tied by winning 9 of the 18 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICCM) was last updated on 6/13/2025 by MarketBeat.com Staff
